1045792-66-2 Usage
Description
CAY10603 is a cell-permeable, active site Zn2+-targeting phenylisoxazolo-hydroxamate that acts as a potent and highly selective HDAC6 inhibitor. It is more potent than SAHA in inhibiting the proliferation of pancreatic cancer cell lines and has shown to be effective in preventing the growth of several pancreatic cancer cell lines.
Uses
Used in Pharmaceutical Industry:
CAY10603 is used as a potent and selective HDAC6 inhibitor for the treatment of pancreatic cancer. It works by inhibiting the deacetylase activity of HDAC6, which is involved in the regulation of microtubule stability and function, and is overexpressed in various cancers, including pancreatic cancer.
Used in Cancer Research:
CAY10603 is used as a research tool for studying the role of HDAC6 in cancer cell growth and proliferation. Its high selectivity for HDAC6 makes it a valuable compound for investigating the specific functions of this enzyme in cancer development and progression.
Used in Drug Development:
CAY10603 is used as a lead compound in the development of new therapeutic agents targeting HDAC6 for the treatment of various cancers, including pancreatic cancer. Its potent inhibitory activity and selectivity for HDAC6 make it a promising candidate for further optimization and development into a clinically useful drug.
Check Digit Verification of cas no
The CAS Registry Mumber 1045792-66-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,4,5,7,9 and 2 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1045792-66:
(9*1)+(8*0)+(7*4)+(6*5)+(5*7)+(4*9)+(3*2)+(2*6)+(1*6)=162
162 % 10 = 2
So 1045792-66-2 is a valid CAS Registry Number.
1045792-66-2Relevant articles and documents
Use of the Nitrile Oxide Cycloaddition (NOC) reaction for molecular probe generation: A new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6
Kozikowski, Alan P.,Tapadar, Subhasish,Luchini, Doris N.,Ki, Hwan Kim,Billadeau, Daniel D.
supporting information; experimental part, p. 4370 - 4373 (2009/05/30)
A series of hydroxamate based HDAC inhibitors containing a phenylisoxazole as the CAP group has been synthesized using nitrile oxide cycloaddition chemistry. An HDAC6 selective inhibitor having a potency of ～2 picomolar was identified. Some of the compounds were examined for their ability to block pancreatic cancer cell growth and found to be about 10-fold more potent than SAHA. This research provides valuable, new molecular probes for use in exploring HDAC biology.
